Ornithine Hydrochloride
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00129 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 14 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | congenital prothrombin deficiency | KG + DL |
| 2 | vitamin deficiency disorder | KG + DL |
| 3 | biotin metabolic disease | KG + DL |
| 4 | atypical coarctation of aorta | KG + DL |
| 5 | aortic malformation | KG + DL |
| 6 | acrodermatitis chronica atrophicans | KG + DL |
| 7 | seborrheic keratosis | KG + DL |
| 8 | seborrheic dermatitis | KG + DL |
| 9 | neonatal dermatomyositis | KG + DL |
| 10 | acne (disease) | KG + DL |
| 11 | hydroa vacciniforme, familial | KG + DL |
| 12 | respiratory syncytial virus infectious disease | KG + DL |
| 13 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | KG + DL |
| 14 | amyopathic dermatomyositis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.